Japan approves two world's first iPS cell therapies
On the 6th of March, 2026, the Japan’s Ministry of Health, Labour and Welfare (MHLV) has granted conditional and time-limited approval to two first-of -a- kind regenerative medicines based on human induced pluripotent stem cells (iPSC).
Recent Approvals
The first one to Sumitomo Pharma for Amchepry, an allogenic iPS
